Deals5 Jun 2025, 08:33 am
Alvotech and Dr. Reddy’s Collaborate to Co-Develop Biosimilar Candidate to Keytruda® for Global Markets
AI Summary
Alvotech and Dr. Reddy’s Laboratories Ltd. have entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda® (pembrolizumab) for global markets. The collaboration aims to speed up the development process and extend the global reach for this biosimilar candidate. The biosimilar candidate is for the treatment of numerous cancer types, with Keytruda® having recorded worldwide sales of USD 29.5 billion in 2024.
Key Highlights
- Alvotech and Dr. Reddy’s to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda® for global markets
- Keytruda® is indicated for the treatment of numerous cancer types
- Worldwide sales of Keytruda were USD 29.5 billion in 2024
- Collaboration combines Dr. Reddy’s and Alvotech’s proven capabilities in biosimilars
- Each party will have the right to commercialize the product globally